Atara Biotherapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ATRA Nasdaq 2830 www.atarabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Atara Biotherapeutics, Inc.

Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise - Apr 2nd, 2026 6:02 pm
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - Apr 1st, 2026 6:01 am
Atara Biotherapeutics: Q4 Earnings Snapshot - Mar 16th, 2026 2:35 pm
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - Mar 16th, 2026 2:05 pm
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Mar 12th, 2026 6:05 am
Pierre Fabre seeks to revive US approval chances for spurned cell therapy - Mar 3rd, 2026 4:52 am
Atara Biotherapeutics Provides a Business Update - Feb 23rd, 2026 6:00 am
Top Midday Decliners - Jan 13th, 2026 12:14 pm
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Jan 12th, 2026 6:00 am
AbbVie buys into PD-1/VEGF sweepstakes; Alnylam and Vertex set expectations - Jan 12th, 2026 4:24 am
Epstein Barr Virus Research Analysis Report 2025-2035: Market Led by AstrViracta, Atara, AlloVir, and Pierre Fabre as Antiviral and Immune-Modulating Therapy Innovation Accelerates - Nov 18th, 2025 8:14 am
Atara Biotherapeutics: Q3 Earnings Snapshot - Nov 12th, 2025 7:11 am
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Nov 12th, 2025 7:00 am
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates - Nov 10th, 2025 6:45 am
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Nov 7th, 2025 4:45 am
Pacira (PCRX) Tops Q3 Earnings Estimates - Nov 6th, 2025 4:10 pm
Adma Biologics (ADMA) Q3 Earnings Match Estimates - Nov 5th, 2025 4:25 pm
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - Nov 3rd, 2025 7:00 am
While institutions own 28% of Atara Biotherapeutics, Inc. (NASDAQ:ATRA), individual investors are its largest shareholders with 35% ownership - Oct 3rd, 2025 4:51 am
Atara Biotherapeutics (ATRA) Soars 10.0%: Is Further Upside Left in the Stock? - Sep 25th, 2025 7:28 am